S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
NASDAQ:CDTX

Cidara Therapeutics (CDTX) Stock Price, News & Analysis

$0.84
+0.10 (+13.48%)
(As of 03/27/2024 ET)
Today's Range
$0.74
$0.85
50-Day Range
$0.64
$0.84
52-Week Range
$0.59
$1.48
Volume
1.44 million shs
Average Volume
530,576 shs
Market Capitalization
$76.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.67

Cidara Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
454.2% Upside
$4.67 Price Target
Short Interest
Healthy
0.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
1.44mentions of Cidara Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$40,490 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.28) to ($0.65) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.55 out of 5 stars

Medical Sector

133rd out of 939 stocks

Biological Products, Except Diagnostic Industry

17th out of 157 stocks

CDTX stock logo

About Cidara Therapeutics Stock (NASDAQ:CDTX)

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

CDTX Stock Price History

CDTX Stock News Headlines

Cidara Therapeutics, Inc. (CDTX)
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Cidara Therapeutics, Inc.
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Cidara Therapeutics Granted Nasdaq Listing Extension
See More Headlines
Receive CDTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/28/2024
Next Earnings (Estimated)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CDTX
Fax
N/A
Employees
73
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.67
High Stock Price Target
$6.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+454.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-29,800,000.00
Pretax Margin
-53.14%

Debt

Sales & Book Value

Annual Sales
$64.29 million
Book Value
($0.04) per share

Miscellaneous

Free Float
83,886,000
Market Cap
$76.31 million
Optionable
Optionable
Beta
0.95
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Jeffrey L. Stein Ph.D. (Age 69)
    President, CEO & Executive Director
    Comp: $873.25k
  • Dr. Preetam Shah M.B.A. (Age 51)
    Ph.D., CFO, Chief Business Officer & Principal Accounting Officer
    Comp: $577.85k
  • Dr. Taylor Sandison (Age 52)
    Chief Medical Officer
    Comp: $632.05k
  • Dr. Kevin M. Forrest Ph.D. (Age 47)
    Founder and Chief Strategy Officer
    Comp: $333.31k
  • Mr. Shane M. Ward (Age 49)
    COO & Chief Legal Officer
  • Ms. Allison Lewis CCP
    SPHR, Senior Vice President of People & Culture
  • Dr. Leslie Tari Ph.D. (Age 57)
    Chief Scientific Officer
    Comp: $845.1k
  • Ms. Laura A. Navalta
    Senior Vice President of Clinical Operations
  • Dr. Nicole Davarpanah J.D.
    M.D., Senior VP of Translational Research & Development

CDTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Cidara Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CDTX shares.
View CDTX analyst ratings
or view top-rated stocks.

What is Cidara Therapeutics' stock price target for 2024?

3 Wall Street analysts have issued 1 year price targets for Cidara Therapeutics' shares. Their CDTX share price targets range from $3.00 to $6.00. On average, they anticipate the company's share price to reach $4.67 in the next year. This suggests a possible upside of 454.2% from the stock's current price.
View analysts price targets for CDTX
or view top-rated stocks among Wall Street analysts.

How have CDTX shares performed in 2024?

Cidara Therapeutics' stock was trading at $0.7940 at the beginning of the year. Since then, CDTX shares have increased by 6.1% and is now trading at $0.8421.
View the best growth stocks for 2024 here
.

Are investors shorting Cidara Therapeutics?

Cidara Therapeutics saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 179,500 shares, a drop of 18.9% from the February 29th total of 221,400 shares. Based on an average daily trading volume, of 713,100 shares, the short-interest ratio is presently 0.3 days.
View Cidara Therapeutics' Short Interest
.

When is Cidara Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our CDTX earnings forecast
.

How were Cidara Therapeutics' earnings last quarter?

Cidara Therapeutics, Inc. (NASDAQ:CDTX) released its earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.01. The biotechnology company had revenue of $7.08 million for the quarter, compared to the consensus estimate of $3.62 million. Cidara Therapeutics had a negative trailing twelve-month return on equity of 264.84% and a negative net margin of 55.49%.

What other stocks do shareholders of Cidara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Verastem (VSTM), Dynavax Technologies (DVAX), Micron Technology (MU), Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE) and Catalyst Pharmaceuticals (CPRX).

When did Cidara Therapeutics IPO?

Cidara Therapeutics (CDTX) raised $60 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

Who are Cidara Therapeutics' major shareholders?

Cidara Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.70%), Vanguard Group Inc. (3.69%), Nantahala Capital Management LLC (1.71%), GSA Capital Partners LLP (0.60%), Northern Trust Corp (0.18%) and Virtu Financial LLC (0.11%). Insiders that own company stock include Brady Johnson, Jeffrey Stein, Jessica Oien, Leslie Tari, Neil Abdollahian, Paul Daruwala, Preetam Shah, Shane Ward, Taylor Sandison and Timothy R Franson.
View institutional ownership trends
.

How do I buy shares of Cidara Therapeutics?

Shares of CDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CDTX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners